Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices
Bills allowing pharmacies to substitute biosimilars for reference biologics have been enacted in all but six states. Interactive map notes state-by-state provisions.
You may also be interested in...
The advisory committee route for approving a first biosimilar to a reference product is no longer necessarily the norm, going by FDA's recent approval of Mylan/Biocon's pegfilgrastim-jmdb, which references Amgen’s Neulasta; agency’s view that a meeting was not needed should encourage other biosimilar aspirants.
Pharmacy chains object to J&J agreements with insurers that block coverage of Pfizer and Merck biosimilars except in 'rarest of circumstances'; seek overcharge damages for Remicade purchases.
Fulphila (pegfilgrastim-jmbd) to launch in US soon; Mylan overcomes complete response letter and gets approval without advisory committee review.